TL;DR — What New Mexico Medicaid Actually Covers

Key structural facts: New Mexico is Pattern #33 in this 50-state series — the only state to affirmatively cover the full legacy stimulant + lipase-inhibitor AOM panel with PA while explicitly listing all four modern GLP-1/melanocortin AOMs as “Not Covered” on a single published page. No carve-outs exist for any modern indication (MACE, MASH, OSA, monogenic obesity). The HCA Director of Pharmacy position (Keenan Ryan, acting CMO) is that HCA is “regularly evaluating” and will “continue to evaluate the possibility of expanding coverage as the landscape evolves” — verbatim, Searchlight NM and Santa Fe New Mexican, November 2025.

Read This First: The KFF YMYL Trap — NM Is on the “Covering” List But Wegovy, Zepbound, Saxenda, and Imcivree Are Explicitly Not Covered

The federal authority at 42 U.S.C. § 1396r-8(d)(2)(A) permits states to exclude “Agents when used for anorexia, weight loss, or weight gain.” New Mexico has partially invoked this authority: excluding modern GLP-1 AOMs while carving in older sympathomimetic and lipase-inhibitor agents as an administrative policy decision. The KFF tracker’s binary covered/not-covered classification cannot capture this two-column architecture. Patients should rely on the HCA Weight Reduction Medications page ( hca.nm.gov/weight-reduction-medications/) as the operative primary source.

NMAC 8.324.4.14(A)(8): The Categorical Regulatory Exclusion

The canonical New Mexico regulatory exclusion is found in the New Mexico Administrative Code, Title 8 (Social Services), Chapter 324 (Adjunct Services), Part 4 (Pharmacy Services), Section 14 (Noncovered Services). Verbatim from the State Records Center & Archives (srca.nm.gov), verified 2026-05-10:

“8.324.4.14 NONCOVERED SERVICES OR SERVICE RESTRICTIONS:

Pharmacy services are subject to the limitations and coverage restrictions that exist for other MAD services.

A. MAD does not cover the following specific pharmacy items: ... (8) weight loss/weight control drugs;

[8.324.4.14 NMAC - Rp, 8.324.4.14 NMAC, 1/1/2014]”

NMAC 8.324.4.14(A)(8) is narrower than the federal floor: the federal statute covers “anorexia, weight loss, or weight gain” while NM uses “weight loss/weight control drugs.” The rule was last readopted January 1, 2014. Amendment requires HCA Medical Assistance Division rulemaking under the New Mexico State Rules Act (NMSA Chapter 14, Article 4). The NMAC remains the canonical regulatory authority; the HCA Weight Reduction Medications page operates as supplemental administrative coverage policy layered above it.

Structural comparison: NM’s exclusion is analogous to Louisiana’s LDH PBM Provider Manual Ch. 37 § 37.5.4 (“Anorexics — Medicaid does not reimburse for anorexics with the exception of orlistat”) and Colorado’s 10 CCR 2505-10 § 8.800.4.B.2.a. All three states use categorical regulatory exclusion with federal-floor language as the framework. NM is more permissive than LA on the legacy AOM panel (six covered vs. orlistat-only); NM is more restrictive than LA on modern GLP-1 carve-outs (zero vs. Wegovy-CV + Zepbound-OSA).

Six Older AOMs Covered with Prior Authorization — HCA Weight Reduction Medications Page (Verbatim)

The HCA Weight Reduction Medications page (hca.nm.gov/weight-reduction-medications/, verified 2026-05-10) opens with the verbatim statement:

“Weight Reduction Medications. Some weight loss medications for treating obesity are covered under the New Mexico Medicaid Fee-for-Service program with prior authorization.”

The page then presents a two-column table — reproduced verbatim below, including the apparent typographical errors and naming inconsistencies in the primary source:

Three primary-source documentation findings flagged by this review — the article reproduces the HCA list exactly as published and does not correct it:

1. Meridia (sibutramine) was withdrawn from the U.S. market on October 8, 2010 by Abbott Laboratories following the SCOUT trial cardiovascular safety signal (increased risk of MI and stroke). Meridia is not clinically available in the U.S. Its continued listing on the HCA Weight Reduction Medications page indicates the page has not been updated in 15+ years.
2. “Didres” is a typographical error for Didrex, the brand name for benzphetamine (Schedule III anorectic sympathomimetic). The HCA page uses “Didres” throughout.
3. “Tenuate (phendimetrazine)” contains a naming mismatch. Tenuate is the brand name for diethylpropion; phendimetrazine is marketed as Bontril and Plegine. The HCA page appears to conflate two distinct DEA Schedule III anorectic sympathomimetics.

PA criteria (verbatim from the HCA page):

“Prior Authorization Criteria: BMI >40 or BMI > 35 with additional risk factors (hypertension, diabetes, dyslipidemia), and a six-month trial of caloric restriction and exercise is recommended (not required).”

“Prior Authorization Process: Providers: to obtain prior authorization, when necessary, fax MAD Form 635 to Medical Assistance division at 505-827-3185. Authorization is for an initial three-month period. Authorization for Meridia and Xenical is continued for a period of one year with significant weight loss (at least 3% body weight loss) and improvement of co-morbid conditions. Prior approval expires after a three-month period for all drugs indicated for short-term weight loss.”

Four structural features of these PA criteria worth noting:

• BMI threshold (BMI > 40 or > 35 + comorbidity) is the bariatric-surgery-equivalent threshold — among the most restrictive in this 33-state series. FDA labeling for most chronic-weight-management drugs uses BMI ≥ 30 or ≥ 27 with comorbidity.
• Six-month lifestyle trial is “recommended (not required)” — administratively more flexible than the hard-gated 3-6 month trial requirements found in most states.
• Initial approval is three months only — the shortest initial-approval window in the series; most states approve 6 months.
• Only Meridia and Xenical have a one-year renewal pathway. The four stimulant AOMs (Didres/Fastin/Sanorex/Tenuate) are approved only for the 3-month short-term period consistent with their FDA labels.

Modern GLP-1 Exclusion: Wegovy, Zepbound, Saxenda, Imcivree, Foundayo — All Explicitly Not Covered

New Mexico has zero modern AOM carve-outs — the strictest position among the 33 states profiled so far:

• No Wegovy-MACE carve-out (unlike NV, CO, LA, NY, AL, OK, IA, WA, CT, MA)
• No Wegovy-MASH carve-out (unlike CA, CO, OK, CT, IA, MA)
• No Zepbound-OSA carve-out (unlike CO, OK, AL, CT, LA, IA, MA)
• No Imcivree-monogenic carve-out (unlike OK)

MCO-level confirmation — BCBSNM verbatim:

“Which drug categories are not covered by the Plan drug list? The following drug categories are not covered by your Blue Cross Community Centennial health plan: Anorexia, weight loss, or weight gain drugs ...”

UHC NM Medicaid PDL verbatim:

“The following drug categories are excluded from coverage under the outpatient pharmacy benefit and are not part of the UnitedHealthcare Community Plan PDL: DESI drugs; Anti-obesity agents; Experimental / research drugs.”

Internal UHC PDL inconsistency (do not mis-cite): Page 545 of the UHC NM Medicaid PDL excludes “Anti-obesity agents” categorically; page 2638 of the same document lists Wegovy as Tier 2 with PA and QL under “Anti-Obesity Agents - Drugs for Weight Loss.” This is the parent national PDL with an NM-specific exclusion layer. The exclusion layer governs in operation; Wegovy is not paid under UHC NM Medicaid. Do not cite the Tier-2 listing as evidence of coverage.

Molina NM Medicaid verbatim policy statement: “In states where weight loss drugs are a benefit exclusion, Wegovy (semaglutide) injection and tablets are considered a benefit exclusion for all indications, including weight reduction, chronic weight management, and weight reduction to lower risk for repeat cardiovascular events.” New Mexico is one of those states.

Note on Saxenda vs. Victoza: Saxenda (liraglutide 3 mg) is explicitly “Not Covered” on the HCA page. Victoza (liraglutide for T2DM) IS covered on MCO formularies for the diabetes indication. The same active ingredient at different doses/indications produces different coverage outcomes.

HSD → HCA Consolidation (July 1, 2024) and the Turquoise Care Rebrand

Two major administrative changes took effect simultaneously on July 1, 2024:

1. Senate Bill 16 of the 2023 NM Legislative Session (Health Care Authority Act) — signed by Governor Michelle Lujan Grisham — consolidated the former Human Services Department (HSD), the State Employee Benefits team (GSD), the Developmental Disabilities Supports Division + Division of Health Improvement (DOH), and the Health Care Affordability Fund (OSI) into a single executive department: the New Mexico Health Care Authority (HCA). Cabinet Secretary: Kari Armijo, Senate-confirmed February 11, 2024.
2. Turquoise Care launched as the new brand for New Mexico Medicaid managed care, replacing Centennial Care 2.0 (January 1, 2019 – June 30, 2024). The CMS-approved 1115 demonstration is approved through December 31, 2028. Verbatim from the HCA Turquoise Care page: “Turquoise Care is the New Mexico Medicaid Managed Care program that began on July 1, 2024.”

The HSD→HCA consolidation did not amend pharmacy coverage policy. NMAC 8.324.4.14(A)(8) survived unchanged. The HCA Weight Reduction Medications page replaced the legacy HSD page at the same content with the same two-column list. Documents published before July 1, 2024 reference HSD; current documents reference HCA. Legacy hsd.state.nm.us URLs still resolve but hca.nm.gov is authoritative for current policy.

HCA mission statement (post-consolidation): “We ensure that New Mexicans attain their highest level of health by providing whole-person, cost-effective, accessible, and high-quality health care and safety-net services.”

The Four Turquoise Care MCOs, Their PBMs, and FFS Conduent

New Mexico’s pharmacy benefit is the most heterogeneous in this 33-state series: five separate PBMs operate in parallel (Conduent for FFS plus four MCO-specific PBMs). Importantly, New Mexico is one of five states in the country without a statewide Medicaid Preferred Drug List (PDL) as of 2026-05-10 — each MCO operates its own formulary.

Western Sky Community Care (Centene) is NOT a current MCO. Western Sky did not win a contract under the Turquoise Care 2024 procurement and exited as of June 30, 2024. Presbyterian was additionally awarded the single Children in State Custody contract — all NM children in state custody enroll with Presbyterian.

FFS contact numbers (Conduent): Provider line 1-800-299-7304; Member line 1-800-283-4465. For GLP-1 legacy-AOM PA: fax MAD Form 635 to MAD at 505-827-3185 regardless of plan.

Prime Therapeutics Procured to Implement Statewide PDL in 2026

Per the LFC (Legislative Finance Committee) Pharmaceutical Update Briefing to the Legislative Health and Human Services Committee, November 2025 (slide 9, verbatim):

“NM’s Medicaid program is implementing a statewide preferred drug list (PDL) standardizing medication coverage and ending variable formularies across MCOs and fee-for-service. A preferred drug list is a standardized list of medications the state recommends over others in the same therapeutic class based on clinical effectiveness and value. PDL will simplify prescribing and increase transparency and accessibility. PDL will focus on high-cost drug classes and not apply step therapy or prior authorization to medications used to treat rare diseases, autoimmune conditions, cancer, or substance use disorder.Prime Therapeutics was recently procured as the vendor to implement PDL. New Mexico Medicaid is one of few states not collecting pharmaceutical supplemental rebates. PDL will help with advancing collection of Medicaid pharmaceutical supplemental rebates.”

And from LFC slide 10: “For Fee-for-Service Medicaid: 45 states and the District of Columbia have a PDL — New Mexico does not currently have a PDL.”

The combined HCA Pharmacy and Therapeutics (P&T) Committee + Drug Utilization Review (DUR) Board held its first quarterly meeting on January 16, 2026 in Albuquerque to begin PDL clinical review. The PDL implementation is a cost-containment initiative (supplemental-rebate capture), not a coverage-expansion initiative. NM’s Ozempic reimbursement grew from $24,409 (2019) to $28,848,544 (2024) — a more than 1,180× increase over five years — the structural concern cited by HCA in declining to expand GLP-1-for-obesity coverage.

AI/AN Tribal Health: 100% FMAP at IHS + Wegovy Still Excluded

New Mexico has the largest Native American population per capita among lower-48 states (~11% AI/AN, primarily Navajo, Pueblo, and Apache). The HCA Native Americans page states verbatim:

“Most Native Americans enrolled in Medicaid may choose to be in Turquoise Care, but are not required to participate in managed care. Native Americans can always go to Indian Health Services or Tribal clinics and hospitals for health care services, whether they are in Fee-for-Service Medicaid or Turquoise Care.”

Under Section 1905(b) of the Social Security Act as amended by the Indian Health Care Improvement Act, services rendered by IHS or tribal facilities to Medicaid-eligible AI/AN beneficiaries are reimbursed at 100% Federal Medical Assistance Percentage (FMAP) — meaning zero state-share cost for those services.

The 100% FMAP enhancement does NOT change which drugs are covered. NMAC 8.324.4.14(A)(8) and the HCA Weight Reduction Medications page apply identically to IHS-rendered prescriptions filled through Conduent FFS or MCO formularies. A Navajo Area IHS physician cannot prescribe Wegovy for chronic weight management and have NM Medicaid reimburse it.

Navajo Nation cross-jurisdictional note: The reservation spans NM, AZ, and UT. GLP-1 coverage for Navajo Nation members varies by state of residence — the same member on the AZ side (AHCCCS territory) may receive a different coverage outcome than a member on the NM side. New Mexico’s exclusion is categorical; Arizona similarly lacks Wegovy obesity coverage (see Arizona Medicaid GLP-1 coverage analysis).

SB 193 (2025) Died January 29, 2025 — And Would Not Have Applied to Medicaid Even If Enacted

Senate Bill 193 of the 2025 First Regular Session (57th Legislature) — “Weight Loss Drugs Insurance Coverage Act” was introduced January 23, 2025. Primary sponsors: Senators Micaelita Debbie O’Malley (D-13), Michael Padilla (D-14), Angel M. Charley (D-30), and Antoinette Sedillo Lopez. Verbatim bill title: “AN ACT RELATING TO INSURANCE; REQUIRING HEALTH INSURERS TO PROVIDE COVERAGE FOR WEIGHT LOSS DRUGS.”

The bill’s operative sections would have required “at least one injectable glucagon-like peptide-1 receptor agonist that is prescribed for chronic weight management in adults with obesity” across:

• Section 1 — Health Care Purchasing Act (state/public employee plans)
• Section 2 — NMSA Chapter 59A Article 22 (individual/group health insurance)
• Section 3 — NMSA Chapter 59A Article 23 (group blanket insurance)
• Section 4 — Health Maintenance Organization Law
• Section 5 — Nonprofit Health Care Plan Law
• Section 6 — Effective for policies issued or renewed on or after January 1, 2026

Bill status: Sent to STBTC (Senate Tax, Business and Transportation Committee) with referrals STBTC/SFC on January 29, 2025. Action postponed indefinitely the same day without a hearing. Bill died.

No 2026 Regular Session successor bill (57th Legislature, 2nd Regular Session, January 20 – February 19, 2026) has been introduced as of 2026-05-10. The dominant 2026 healthcare legislation was HB 4 (Health Care Affordability Fund, Rep. Reena Szczepanski — passed) and HB 2 (budget). Neither addresses Medicaid GLP-1 coverage.

Comparison with analogous bills:

• Colorado SB 25-048 (structural parallel) — also amended only commercial statutes, not Medicaid; signed June 3, 2025, effective January 1, 2027. CO’s commercial bill passed; NM’s died.
• Nevada SB 244 (structural contrast) — DID amend the Medicaid statute (NRS 422.4025) but died in money committee June 3, 2025 due to a $165.4 million biennium cost projection. NM’s SB 193 never included Medicaid.

Appeals: HCA Fair Hearings via OAC (NMSA 27-3-3)

Statutory anchor — NMSA 27-3-3 (verbatim):

“27-3-3. Fair hearing. An applicant for or recipient of public assistance who is aggrieved because of the department’s decision or delay in making a decision shall have the right to a fair hearing in accordance with the rules of the department. Notice of the right to a fair hearing shall be in writing and shall be given to the applicant or recipient at the time of any administrative action which adversely affects the applicant or recipient. The hearing shall be held in accordance with the rules of the department and any final administrative decision shall be in writing, with a copy provided to the applicant or recipient.”

Two-track appeal structure:

• Track 1 (Turquoise Care MCO members): Internal MCO appeal first (NMAC 8.308.15). MCO must acknowledge within 5 business days; decide standard appeal within 30 calendar days (extendable 14 days); decide expedited appeal within 72 hours. Written decision required.
• Track 2 (State Fair Hearing): Request within 90 days of the MCO’s internal appeal decision (for MCO members) or the FFS adverse action notice. Administered by the HCA Office of Administrative Continuations (OAC) under NMAC 8.352. An Administrative Law Judge who was not involved in the original action presides. Judicial review available in NM District Court under NMSA Chapter 14, Article 4 (State Rules Act) after exhausting administrative remedies.

Practical note for modern GLP-1 denials: Because the categorical exclusion at NMAC 8.324.4.14(A)(8) is a regulatory bar — not a PA-criteria judgment call — the fair-hearing path for Wegovy/Zepbound/Saxenda/Imcivree chronic weight management denials faces a high standard. An Administrative Law Judge cannot override a regulation; the member would need to argue that the denial was procedurally improper, or that the specific indication falls outside the “weight loss/weight control” exclusion (a difficult argument given the HCA page explicitly lists the drug as “Not Covered”). For T2DM GLP-1 PA denials, the fair-hearing path is more viable since those are covered with criteria.

How NM Compares: Louisiana, Nevada, and Arizona Analogues

New Mexico occupies a structurally unique position in this series:

NM is directionally opposite to NV: NV is more permissive on Wegovy-MACE; NM is more permissive on the legacy stimulant panel. NM and AZ share the Western-state regulatory-exclusion architecture but NM’s legacy-AOM carve-in is operative (drugs actually paid), while AZ’s clinical policy for those same drugs is operationally moot under the parent contractor exclusion.

What NM Medicaid Members Can Do in 2026

1. Check legacy AOM eligibility. If your BMI is > 40 (or > 35 with hypertension, diabetes, or dyslipidemia), orlistat (Xenical) or phentermine (Fastin) may be covered with PA. Ask your prescriber to fax MAD Form 635 to 505-827-3185. Orlistat is the only chronic-use option in the covered list; phentermine is approved for up to 12 weeks.
2. Confirm your MCO and PBM. For T2DM GLP-1 PA (Ozempic, Mounjaro, Trulicity), contact your plan’s PBM directly: BCBSNM (Prime Therapeutics, 1-866-689-1523), Molina (CVS Caremark, 1-844-862-4543), Presbyterian (Capital Rx, 1-888-977-2333), UHC (OptumRx, 1-877-236-0826).
3. For type-2 diabetes GLP-1 coverage: All four MCOs cover GLP-1 receptor agonists for the FDA-approved T2DM indication with PA. This is separate from the obesity-indication exclusion.
4. Appeal a denial within 90 days. While the categorical exclusion at NMAC 8.324.4.14(A)(8) is a high bar to overcome, fair hearings are available and the process is relatively straightforward. See the GLP-1 insurance appeal playbook for general appeal strategy.
5. Monitor the 2026 statewide PDL implementation. The HCA P&T/DUR Committee began meeting in January 2026. A statewide PDL could reshape the formulary landscape — though the LFC briefing frames this as cost-containment, not coverage expansion.
6. IHS or tribal facility members: You may choose FFS Medicaid rather than a Turquoise Care MCO. Under FFS, the Conduent PBM processes claims (BIN 028165 / PCN DRNMPROD). Coverage rules are identical; Wegovy/Zepbound/Saxenda/Imcivree are excluded regardless of facility type.

Sources

1. NMAC 8.324.4.14(A)(8) — New Mexico Administrative Code, Title 8, Chapter 324, Part 4, Section 14(A)(8). State Records Center & Archives (srca.nm.gov). Verified 2026-05-10.
2. HCA Weight Reduction Medications page — hca.nm.gov/weight-reduction-medications/. Verified 2026-05-10.
3. 42 U.S.C. § 1396r-8(d)(2)(A) — Social Security Act § 1927(d)(2)(A). Federal optional exclusion for weight-loss agents.
4. NMSA 27-3-3 — New Mexico Statutes Annotated 1978, Chapter 27 (Public Assistance), Article 3 (Appeals), Section 3 (Fair hearing).
5. Senate Bill 16 of 2023 NM Legislative Session (Health Care Authority Act) — signed by Governor Lujan Grisham, effective July 1, 2024.
6. Senate Bill 193 of 2025 NM Regular Session — nmlegis.gov/Sessions/25%20Regular/bills/senate/SB0193.pdf. Verified 2026-05-10.
7. HCA Turquoise Care page — hca.nm.gov/turquoise-care/. CMS 1115 demonstration approval July 25, 2024; period through December 31, 2028. Verified 2026-05-10.
8. HCA Pharmacy Benefit Contacts page — hca.nm.gov/pharmacy-benefit-contacts/. FFS Conduent BIN/PCN + 4 MCO PBM contacts. Verified 2026-05-10.
9. LFC Pharmaceutical Update Briefing — presented to NM Legislative Health and Human Services Committee, November 2025. Slides 8-10: Ozempic reimbursement growth, statewide PDL implementation, Prime Therapeutics procurement.
10. BCBSNM Blue Cross Community Centennial Drug List — verbatim exclusion: “Anorexia, weight loss, or weight gain drugs.” Verified 2026-05-10.
11. UnitedHealthcare Community Plan of NM PDL — p. 545: “Anti-obesity agents” categorical exclusion. Verified 2026-05-10.
12. Molina Healthcare of NM Medicaid Formulary — parent policy: Wegovy excluded for all indications in weight-loss-exclusion states. Verified 2026-05-10.
13. HCA Native Americans page — hca.nm.gov/lookingforassistance/native_americans/. Tribal FFS election + 100% FMAP for IHS-rendered services. Verified 2026-05-10.
14. Searchlight NM (November 2025) + Santa Fe New Mexican (November 2025) — Keenan Ryan (acting CMO, Director of Pharmacy, HCA) verbatim: HCA “regularly evaluating” and will “continue to evaluate the possibility of expanding coverage as the landscape evolves.”
15. Source NM (April 28, 2025) — NM Medicaid “does not cover Wegovy” confirmed.
16. KFF State Medicaid Coverage of Obesity Medications tracker (January 2026) — NM listed as “covering” state; see YMYL trap section above for accurate indication-level context.
17. NMAC 8.308.15 — Managed Care grievances and appeals; MCO internal appeal timeline requirements. srca.nm.gov. Verified 2026-05-10.
18. NMAC 8.352 — HCA fair-hearing regulations. srca.nm.gov. Verified 2026-05-10.

Frequently Asked Questions

Related Articles

• GLP-1 Insurance Coverage: Medicare, Medicaid, and Commercial Plans — 50-State Taxonomy
• Louisiana Medicaid GLP-1 Coverage (Pattern #28): Wegovy MACE + Zepbound OSA Carve-Outs with Patient Treatment Agreement
• Nevada Medicaid GLP-1 Coverage (Pattern #31): Sole Wegovy CV-Only Carve-Out — Most Restrictive in Series
• Arizona Medicaid (AHCCCS) GLP-1 Coverage (Pattern #12): Agency-Manual Exclusion
• GLP-1 Insurance Denial Appeal Playbook: How to Fight a Coverage Rejection